ジェネリック医薬品の世界市場予測2016-2026

◆英語タイトル:Generic Drugs Market Forecast 2016-2026
◆商品コード:VGAIN60631
◆発行会社(調査会社):visiongain
◆発行日:2016年4月
◆ページ数:306
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Sigle User(1名利用)GBP1,999 ⇒換算¥283,858見積依頼/購入/質問フォーム
Five UserGBP2,999 ⇒換算¥425,858見積依頼/購入/質問フォーム
Site License(全社内共有可)GBP4,999 ⇒換算¥709,858見積依頼/購入/質問フォーム
※visiongain社発行の調査レポートは、Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。

販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongain社の日本における正規販売代理店です。visiongain社の概要及び新刊レポートはこちらでご確認いただけます。
当調査レポートでは、ジェネリック医薬品の世界市場について調査・分析し、以下の構成でお届けいたします。
1. レポート概要

2. ジェネリック医薬品の概要

3. ジェネリック医薬品市場 2016-2026

4. 米国のジェネリック医薬品市場 2016-2026

5. 主要な欧州のジェネリック医薬品市場 2016-2026

6. アジア太平洋のジェネリック医薬品市場2016-2026

7. 新興ジェネリック医薬品市場 2016-2026

8. ジェネリック医薬品市場における主要企業 2016-2026

9. ジェネリック医薬品市場の定性分析 2016-2026

10. 結論

11. 用語集
【レポートの概要】

What can be expected from the Generic Drugs Market? Which areas are going to grow at the fastest rates? This visiongain report shows you potential revenues to 2026, assessing data, trends, opportunities and prospects.

Our 306-page report provides 175 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales across all the major regional and national generic drugs market. You will see financial results, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market.

Forecasts from 2016-2026 and other analyses show you commercial prospects
Besides revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT analysis) and commercial developments.

See detailed profiles or revenue forecasts for some of the leading regions in the generic drugs market
• US
• EU5
• Asia-Pacific
• Emerging markets
See revenue forecasts for the leading international markets
How will leading national and regional markets perform to 2026? Our study forecasts revenues in national markets, including:
• US
• Germany
• UK
• France
• Italy
• Spain
• China
• Japan
• India
• Brazil
• Russia
• Mexico
• South Korea
• Turkey

Leading companies and potential for market growth
Visiongain forecasts overall revenue for the Generic Drugs Market will reach $254.6bn in 2016. We predict a high revenue growth over the forecast period driven by an ageing population, healthcare cost saving strategies and rapid growth of emerging economies.

Our work analyses the key companies in the market. See visiongain’s analysis of ten leading companies, including:
• Teva
• Novartis (Sandoz)
• Allergan
• Mylan
• Pfizer
• Abbott
• Sun Pharma
• Aspen
• Fresenius Kabi
• Sanofi

A company profile gives you the following information where available:
• Discussion of a company’s activities and outlook
• Generic drugs revenue and share of total revenue
• Historic revenue (where available), analysis and discussion of company performance
• Analysis of major products currently on the market
• Acquisitions and strategic partnerships

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

What issues will affect the generic drugs industry?
Our new report discusses issues and events affecting the generic drugs market. You will find discussions, including qualitative analyses:
• Highly fragmented and competitive market with significant variations in different geographic regions
• Changing political and regulatory landscape changing the prospects of future products and reimbursement opportunities
• Future generic drug opportunities

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.

How the Generic Drugs Market Forecast 2016-2026: Growth in Leading Regional and National Markets report helps you
In summary, our 306-page report gives you the following knowledge:
• Revenue forecasts to 2026 for the Generic Drugs market – discover the industry’s prospects, finding promising places for investments and revenues
• Revenue forecasts to 2026 for major regional markets – US, EU5, Asia-Pacific, Emerging markets
• Revenue forecasts to 2026 for fourteen leading national markets – US, Germany, UK, France, Italy, Spain, China, Japan, India, Brazil, Russia, Mexico, South Korea and Turkey
• Assessment of leading companies – analysis of products, revenue (where available), mergers & acquisitions, and pipelines
• Discussion of what stimulates and restrains companies and the market
• Prospects for established firms and those seeking to enter the market

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunities. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain’s study is for everybody needing commercial analyses for the generic drugs market and leading companies. You will find data, trends and predictions. Please order our report now.

【レポートの目次】

1. Report Overview
1.1 Global Generic Drugs: Market Overview
1.2 Global Generic Drugs Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered By This Analytical Report
1.6 Who Is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain

2. An Introduction to Generic Drugs
2.1 An Introduction to the Rise of Generic Drugs
2.2 What Are Generic Drugs?
2.2.1 Generic Active Ingredients
2.3 A Brief Overview of the Pharmaceutical Industry
2.3.1 Brief History of Generic Drugs
2.3.2 The Hatch-Waxman Act: The Rise of Generics
2.4 Demonstrating Bioequivalence: A Major Factor in Approving Generics
2.5 Types of Generics – Authorised, Branded and Unbranded
2.6 Complex Generics
2.7 Classification of Generic Drugs Markets
2.8 Is Generic Substitution Bad News for Big Pharma Business?
2.8.1 The ‘Evergreening’ of Pharmaceutical Products
2.9 Regulation of Generic Drugs
2.9.1 Regulation in the US
2.9.2 Regulation in Europe
2.9.3 Regulation in Japan
2.9.4 Regulation in China
2.10 Compulsory Licensing
2.11 Market Definition and Scope of This Report
2.11.1 Market Sizing and Revenue Reporting
2.11.2 Currency Exchange Rates in This Report

3. Generic Drugs Market 2016-2026
3.1 The Global Generic Drugs Market: Market Overview
3.1.1 Segmenting the Global Generic Drugs Market
3.2 The Rise of the Global Generic Drugs Market in 2015
3.3 Changes in the Regional Distribution of the Generic Drugs Market 2014-2015
3.4 The Global Generic Drugs Market: Sales Forecast 2016-2026
3.5 Generic Drugs: Regional Market Forecast: 2016-2026
3.5.1 Changes in Generic Drug Regional Market Shares 2016-2026
3.6 Leading National Markets for Generic Drugs: Market Forecast 2016-2026
3.7 National Markets that will Drive Generic Drugs Growth
3.8 Changes in Market Shares by National Market 2016-2026
3.9 Drivers and Restraints for the Global Generic Drugs Market 2016-2026

4. US Generic Drugs Market, 2016-2026
4.1 Generic Drugs in the US: Market Overview
4.1.1 The Effects of Generics on Healthcare Spending in the US
4.1.2 The Hatch-Waxman Act and Its Ongoing Effects
4.1.3 Consolidation in the Drug Development and Supply Chain Driving US Generics
4.2 US Historical Generic Penetration Rates
4.3 Leading Companies Operating within the US Generic Drugs Market
4.3.1 The Increasing Acceptance of Generics amongst Consumers
4.3.2 Affordable Care Act: Expanding Medicare Coverage
4.4 The US Generic Drugs Market: Drivers and Restraints 2016-2026
4.5 The US Generic Drugs Market Forecast: 2016-2026
4.6 The US Generic Drugs Market – Strategic Analysis
4.6.1 Will Biosimilars Dictate the Future of the US Generics Market?
4.6.2 The Backlog of ANDA Applications
4.6.3 The Generic Drug User Fee Amendments (GDUFA)
4.6.4 Shortages of Generic Drugs Will Restrain the Market
4.6.5 The Anti-Competitive ‘Pay for Delay’ Effect
4.7 US Generic Drugs Market: A Range of Factors Contributing to Growth

5. Leading European Generic Drug Market, 2016-2026
5.1 European Generic Drugs: Market Overview
5.1.1 The EU5
5.1.2 Why Growth in Some Markets is Being Hindered?
5.1.3 Predominant Pricing Systems and Generic Penetration In European Markets
5.1.4 Will Europe Move towards Free-Pricing Systems?
5.1.5 Challenges in the European Regulatory Environment
5.1.6 Ending Anti-Competitive ‘Pay for Delay’ Tactics in Europe
5.1.7 FDA and EMA Joint Data Sharing and Inspections
5.2 EU5 Generic Drugs Market Forecast: 2016-2026
5.3 EU5 Market Share Breakdown 2016-2026
5.4 Germany: New Reforms to Medicinal Pricing May Impact Market Entry
5.4.1 German Generic Drugs Market: Generic Penetration By Volume, 2000-2015
5.4.2 German Generic Drugs Market: Generic Penetration by Value, 2000-2015
5.5 UK Generic Drugs Market: A Mature Market with Growth Potentials
5.5.1 UK Generic Drugs Market: Sales Forecast 2016-2026
5.5.2 Cost Pressures and Demand-Side Policies Drive UK Generic Penetration
5.5.3 UK Generic Drugs Market: Generic Penetration by Volume, 2000-2015
5.5.4 UK Generic Drugs Market: Generic Penetration by Value, 2000-2015
5.5.5 Pharmacists as Enforcers of Generic Substitution
5.5.6 Pay Time for ‘Pay-For-Delay’
5.5.7 GSK: Widening the Gate to Accessible Medicines
5.6 French Generic Drugs Market: Healthcare Reforms Impacting on Market Growth
5.6.1 French Generic Drugs Market: Sales Forecast 2016-2026
5.6.2 French Generic Drugs Market: Generic Penetration by Volume, 2000-2015
5.6.3 French Generic Drugs Market: Generic Penetration by Value, 2000-2015
5.7 Italian Generic Drugs Market: Branded Generics Hindering Overall Growth
5.7.1 The Tightening of Italy’s Patent Legislations
5.7.2 The Italian Healthcare System – A Tale of Falling Budgets
5.7.3 Italian Generic Drugs Market: Sales Forecast: 2016-2026
5.7.4 Italian Generic Drugs market: Generic Penetration by Volume
5.7.5 Italian Generic Drugs Market: Generic Penetration by Value
5.8 Spain
5.8.1 Cost-Containment Measures Helping to Boost Generic Drug Use
5.8.2 Spanish Generic Drugs Market: Sales Forecast 2016-2026
5.8.3 Spanish Generic Drugs Market: Generic Penetration by Volume, 2000-2015
5.8.4 Spanish Generic Drugs Market: Generic Penetration by Value, 2000-2015

6. Asia-Pacific Generic Drugs Market, 2016-2026
6.1 Generic Drugs in the Asia-Pacific Market: Market Overview
6.2 Chinese Generic Drugs Market: Domestic Companies Dominate the Market Landscape
6.2.1 The Major Drivers of Growth in the Chinese Generics Market
6.2.2 Chinese Generic Drugs Market: Sales Forecast 2016-2026
6.2.3 Compulsory Licensing of Generic Drugs
6.2.4 Expansion of Healthcare Coverage and Reimbursement
6.2.5 Chinese Generic Drugs Market: Generic Penetration by Volume, 2000–2015
6.2.6 Chinese Generic Drugs Market: Generic Penetration by Value, 2000-2015
6.2.7 The Impacts of Price Controls and the Anhui Model
6.3 Japanese Generic Drugs Market: High Barriers to Entry
6.3.1 Public Perception of Generics in Japan
6.3.2 Japanese Generic Drugs Market: Leading Companies
6.3.3 Japanese Generic Drugs Market: Sales Forecast 2016-2026
6.3.4 Japanese Generic Drugs Market: Generic Penetration by Volume, 2000–2015
6.3.5 Japanese Generic Drugs Market: Generic Penetration by Value, 2000-2015
6.3.6 Government Initiatives Driving Generic Penetration
6.3.7 Japanese Attitudes to Generic Drugs
6.4 Indian Generic Drugs Market: Regulatory Failures Hindering Sales Growth
6.4.1 Leading Companies in the Indian Generic Drugs Market
6.4.2 Indian Generic Drugs Market: Sales Forecast 2016-2026
6.4.3 The Reforms to India’s Drug Prices Control Order and Its Likely Effects on Generic Drugs Revenues
6.4.4 Expansion of the National Healthcare Coverage Increases the Need for Generics
6.4.5 Has Recent Manufacturing Quality Failures Dented India’s Generics Growth?

7. Emerging Generic Drugs Market, 2016-2026
7.1 Generic Drugs in the Emerging Market: Market Overview
7.1.1 Emerging Economies: Improving Logistics and Better Infrastructure Catalysing Generics Growth
7.2 Brazil
7.2.1 Brazilian Generic Drugs Market: Sales Forecast 2016-2026
7.2.2 Generics to Facilitate Low-Income Earner’s Access to Medicines
7.2.3 Foreign Generic Drug Manufacturers Entering the Brazilian Market
7.3 Russian Generic Drugs Market: Improving IP Protection to Aid Market Growth
7.3.1 Historical Trends in Russia’s Pharmaceutical Production and Distribution
7.3.2 The Pharma2020 Strategy – Healthcare and Industry Reform
7.3.3 Self-Medication in Russia and the Integral Role of Pharmacies
7.3.4 Russian Generic Drugs Market: Sales Forecast 2016-2026
7.4 Mexico
7.4.1 Government Programmes to Vitalise Generic Penetration in Mexico
7.4.2 Regulatory Changes and the Inception of COFEPRIS
7.4.3 Mexican Generic Drugs Market: Sales Forecast 2016-2026
7.5 South Korea
7.5.1 Pharmaceutical Price Controls and Measures Being Implemented in South Korea
7.5.2 South Korean Generic Drugs Market: Sales Forecast 2016-2026
7.6 Turkey
7.6.1 Cost Cutting Measures and their Effects on Turkish Generics
7.6.2 Will Turkey Become a Production Base for High Technology Products?
7.6.3 Turkish Generic Drugs Market: Sales Forecast 2016-2026
7.6.4 Regulatory Guidelines for Generic Drugs in Turkey
7.6.5 How Effective has Turkey’s Health Transformation Programme Been?

8. Leading Companies in the Generic Drugs market, 2016-2026
8.1 Generic Drugs: Continuous Expansion to Rival
8.1.1 The Leading Companies in the Global Generics Market
8.2 Teva
8.2.1 Teva: Historical Financial and Performance Analysis, 2010-2014
8.2.2 Teva Generic Drugs Sales Forecast 2016-2026
8.2.3 Teva and Allergan Spin-Off Generic Drug Deal
8.2.4 Allergan: Historical Financial and Performance Analysis, 2010-2014
8.2.5 Allergan: Developments in Generic Drug Segment Prior Mega-Deal
8.2.6 Teva: Generic Drugs Portfolio Analysis, 2016
8.2.7 Teva: What Future Moves Could We Expect?
8.3 Novartis
8.3.1 Novartis: Historical Financial and Performance Analysis, 2010-2014
8.3.2 Novartis Generic Drugs Sales Forecast 2016-2026
8.3.3 Novartis Generic Drugs Portfolio Analysis, 2016
8.3.4 What Does the Future Hold for Novartis’ Generic Drugs Business?
8.4 Mylan
8.4.1 Mylan: Historical Financial and Performance Analysis, 2010-2014
8.4.2 Mylan Generic Drugs Sales Forecast 2016-2026
8.4.3 Mylan: Recent Developments
8.4.4 Mylan’s Collaborative Efforts
8.4.5 What Does the Future Hold for Mylan’s Generic Drugs Business?
8.5 Pfizer
8.5.1 Pfizer: Historical Financial and Performance Analysis, 2010-2014
8.5.2 Pfizer’s Restructuring Strategy
8.5.3 Pfizer’s Done Deal with Hospira
8.5.4 Pfizer Generic Drugs Sales Forecast 2016-2026
8.5.5 Hospira: A Brief Overview of Operations
8.5.6 Hospira: Historical Financial and Performance Analysis 2010-2014
8.5.7 Hospira: Recent Developments
8.5.8 Future Prospects for Pfizer’s Generic Business
8.6 Abbott
8.6.1 Abbott: Historical Financial and Performance Analysis, 2010-2014
8.6.2 Abbott Generic Drugs Sales Forecast 2016-2026
8.6.3 Abbott: Recent Developments
8.6.4 What Does the Future Hold for Abbott’s Generic Drugs Business?
8.7 Sun Pharma
8.7.1 Sun Pharma’s Business Areas
8.7.2 Sun Pharma: Historical Financial and Performance Analysis, 2010-2014
8.7.3 Sun Pharma Generic Drugs Sales Forecast 2016-2026
8.7.4 Sun Pharma-Ranbaxy Acquisition
8.8 Aspen
8.8.1 Aspen: Historical Financial and Performance Analysis, 2010-2014
8.8.2 Aspen Generic Sales Forecast 2016-2026
8.8.3 Aspen: Recent Developments
8.8.4 Future Outlook for Aspen’s Generic Business
8.9 Fresenius Kabi
8.9.1 Fresenius Kabi: Historical Financial and Performance Analysis, 2010-2014
8.9.2 Fresenius Kabi Generic Drugs Sales Forecast 2016-2026
8.9.3 InnoPharma Licensing Deal Bolsters Portfolio Grown Via Past Acquisitions
8.9.4 Fresenius Kabi’s Joint Venture with PT Soho Global Health
8.9.5 Future Prospects for Fresenius Kabi’s Generics Business
8.10 Sanofi
8.10.1 Sanofi: Historical Financial and Performance Analysis, 2010-2014
8.10.2 Sanofi Generic Sales Forecast 2016-2026
8.10.3 Sanofi’s Response to Lantus Competition
8.10.4 Sanofi’s Strategies to Develop Generic Sales
8.10.5 Future Prospects for Sanofi’s Generics Business

9. Qualitative Analysis of the Generic Drugs Market, 2016-2026
9.1 Market Factors Influencing the Global Generic Drugs Market
9.2 SWOT Analysis of the Global Generic Drugs Market, 2016-2026
9.2.1 Strengths
9.2.2 Weaknesses
9.2.3 Opportunities
9.2.4 Threats
9.3 Porter’s Five Force Analysis of the Global Generic Drugs Market, 2016-2026
9.3.1 Power of Buyers: Medium
9.3.2 Power of Suppliers: Low
9.3.3 Rivalry among Competitors: High
9.3.4 Threat of New Entrants: High
9.3.5 Threat of Substitutes: Low

10. Conclusions
10.1 Overview of Current Market Conditions and Market Forecast, 2016-2026
10.2 Generic Drugs as a Strategic Tool in Healthcare
10.3 Major Drivers of Growth for Generic Drugs, 2016-2026
10.4 The Regulatory Landscape for Generic Drugs
10.5 Leading Generic Drug Manufacturers
10.6 Future Outlook for the Leading Regions within the Global Generic Drugs Market, 2016-2026
10.7 Generic Penetration by Volume in Leading National Markets
10.8 What Does The Future Hold For The Global Generic Drugs Market?

11. Glossary

Table 1.1 Global Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) by National Markets, 2014-2026 (Redacted Data)
Table 2.1 Types Of Drug Names, 2016
Table 2.2 Currency Exchange Rates, 2015
Table 3.1 The Global Generic Drugs Market Size: Revenue ($bn) and Market Share (%) by Leading National Markets, 2014 and 2015
Table 3.2 The Global Generic Drugs Market Size: Revenue ($bn) and Market Share (%) by Region, 2014 and 2015
Table 3.3 The Global Generic Drugs Market Forecast:: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
Table 3.4 The Global Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) by Region, 2014-2026
Table 3.5 The Global Generic Drugs Market Forecast: Market Share (%) by Region, 2014, 2020, and 2026
Table 3.6 The Global Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) by National Market, 2014-2026
Table 3.6 (cont’d) The Global Generic Drugs Market Forecast:: Revenue ($bn), AGR (%) and CAGR (%) by National Market, 2014-2026
Table 3.7 The Global Generic Drugs Market Forecast: CAGR (%) by National Market, 2014-2020, 2020-2026, 2014-2026
Table 3.8 The Global Generic Drugs Market Forecast: Market Share (%) by National Markets, 2014, 2020, and 2026
Table 3.9 Global Generic Drugs Market Drivers and Restraints, 2014-2026
Table 4.1 US Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%) 2004-2015
Table 4.2 US Generic Drugs Market Drivers and Restraints, 2016-2026
Table 4.3 US Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
Table 5.1 The EU5 Generic Drugs Market: Revenue ($bn) and Market Share (%) by Country, 2014 and 2015
Table 5.2 EU5 Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
Table 5.3 The EU5 Generic Drugs Market: Market Share (%) by Country, 2014, 2020, 2026
Table 5.4 The German Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
Table 5.5 German Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%), 2000-2015
Table 5.6 German Generic Drugs Market: Generic Penetration by Value (%) and AGR (%), 2000-2015
Table 5.7 The UK Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
Table 5.8 UK Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%), 2000-2015
Table 5.9 UK Generic Drugs Market: Generic Penetration by Value (%) and AGR (%), 2000-2015
Table 5.10 The French Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
Table 5.11 French Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%), 2000-2015
Table 5.12 French Generic Drugs Market: Generic Penetration by Value (%) and AGR (%), 2000-2015
Table 5.13 The Italian Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
Table 5.14 Italian Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%), 2000-2015
Table 5.15 Italian Generic Drugs Market: Generic Penetration by Value (%) and AGR (%), 2000-2015
Table 5.16 The Spanish Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and (CAGR%), 2014-2026
Table 5.17 Spanish Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%), 2000-2015
Table 5.18 Spanish Generic Drugs Market: Generic Penetration by Value (%) and AGR (%), 2000-2015
Table 6.1 The Chinese Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
Table 6.3 Chinese Generic Drugs Market: Generic Penetration by Value (%) and AGR (%), 2000-2015
Table 6.4 The Japanese Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
Table 6.5 Japanese Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%), 2000-2015
Table 6.6 Japanese Generic Drugs Market: Generic Penetration by Value (%) and AGR (%), 2000-2015
Table 6.7 The Indian Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
Table 6.8 Leading Drug Types In Indian Pharmaceutical Market: Revenue ($bn) and Market Share (%), 2015, 2020 & 2026
Table 7.1 The Brazilian Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
Table 7.2 The Russian Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
Table 7.3 The Mexican Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
Table 7.4 The South Korean Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
Table 7.5 The Turkish Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
Table 8.1 Top Generic Drugs Manufacturers: Total Revenue ($bn), Generic Drugs Revenue ($bn) and Generic Share of Revenue (%), 2014
Table 8.2 Teva: Company Overview, 2014-2015
Table 8.3 Teva: Historical Generic Drugs Sales ($bn) and AGR (%), 2009-2013
Table 8.4 Teva Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
Table 8.5 Allergan: Company Overview 2014-2015
Table 8.6 Allergan: Historical Generic Drugs Sales ($bn) and AGR (%), 2010-2014
Table 8.7 Novartis: Overview, 2014-2015
Table 8.8 Novartis: Historical Generic Drugs Sales ($bn) and AGR (%), 2010-2014
Table 8.9 Novartis Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
Table 8.10 Mylan: Company Overview, 2014-2015
Table 8.11 Mylan: Historical Generic Drugs Sales ($bn) and AGR (%), 2010-2014
Table 8.12 Mylan: Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
Table 8.13 Pfizer: Company Overview, 2014-2015
Table 8.14 Pfizer: Historical ‘Established Products’ Drugs Sales ($bn) and AGR (%), 2010-2014
Table 8.15 Pfizer: Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
Table 8.16 Hospira: Company Overview, 2013-2014
Table 8.17 Hospira: Historical Specialty Injectables Sales ($bn) and AGR (%), 2010-2014
Table 8.18 Allergan: Company Overview, 2014-2015
Table 8.19 Abbott: Company Overview, 2014-2015
Table 8.20 Abbott: Historical Generic Drugs Sales ($bn) and AGR (%), 2010-2014
Table 8.21 Abbott: Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
Table 8.22 Sun Pharmaceuticals: Company Overview, 2014-2015
Table 8.23 Sun Pharma: Historical Generic Drugs Sales (Rs.bn and $bn), 2010-2014
Table 8.24 Sun Pharma Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
Table 8.25 Aspen: Company Overview, 2014-2015
Table 8.26 Aspen: Historical Revenue ($bn, bn Rand) and AGR (%), 2010-2014
Table 8.27 Aspen Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
Table 8.28 Fresenius Kabi: Company Overview, 2014-2015
Table 8.29 Fresenius Kabi: Historical Generic Drugs Sales (€bn and $bn), 2010-2014
Table 8.30 Fresenius Kabi: Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
Table 8.31 Sanofi: Company Overview, 2014-2015
Table 8.32 Sanofi: Historical Generic Drugs Sales ($bn) and AGR (%), 2010-2014
Table 8.33 Sanofi Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
Table 9.1 SWOT Analysis of the Generic Drugs Market, 2016-2026
Table 9.2 World 65+ Population Forecast: Size (m), AGR (%) and CAGR (%), 2014-2026
Table 10.1 Global Generic Drugs Market Forecast: Revenue ($bn) and CAGR (%), 2014, 2020 and 2026
Table 10.2 Top Generic Drug Manufacturers: Generic Drugs Revenue ($bn) and Market Share (%), 2015
Table 10.3 Global Generic Drugs Market Forecast: Revenue ($bn) by National Markets, 2014, 2020 and 2026
Table 10.4 US, EU5 and Japan Generic Drugs Market Forecast: Revenue ($bn), 2014-2026
Table 10.5 BRIC Generic Drugs Market Forecast: Revenue ($bn), 2014-2026
Table 10.6 Mexico, South Korea, and Turkey Generic Drugs Market Forecast: Revenue ($bn), 2014-2026
Table 10.7 Generic Drug Penetration by Volume in Leading National Markets (%), 2015

Figure 1.1 Global Generic Drugs Market Segmentation
Figure 2.1 EU Data Exclusivity for Generics: Possible Scenarios, 2016
Figure 3.1 The Global Generic Drugs Market Size: Revenue ($bn) by Leading National Markets, 2014
Figure 3.2 The Global Generic Drugs Market Size: Revenue ($bn) by Leading National Markets, 2015
Figure 3.3 The Global Generic Drugs Market Size: Revenue ($bn) by Region, 2014
Figure 3.4 The Global Generic Drugs Market Size: Revenue ($bn) by Region, 2015
Figure 3.5 Global Generic Drugs Market Forecast: ($bn) and AGR (%), 2014-2026
Figure 3.6 The Global Generic Drugs Market Forecast: Market Share (%) by Region, 2014
Figure 3.7 The Global Generic Drugs Market Forecast: Market Share (%) by Region, 2020
Figure 3.8 The Global Generic Drugs Market Forecast: Market Share (%) by Region, 2026
Figure 3.9 The Global Generic Drugs Market Forecast: CAGR (%) by National Market, 2014-2020
Figure 3.10 The Global Generic Drugs Market Forecast: CAGR (%) by National Market, 2020-2026
Figure 3.11 The Global Generic Drugs Market Forecast: CAGR (%) by National Market, 2014-2026
Figure 3.12 The Global Generic Drugs Market Forecast: Market Share (%) by National Markets, 2014
Figure 3.13 The Global Generic Drugs Market Forecast: Market Share (%) by National Markets, 2020
Figure 3.14 The Global Generic Drugs Market Forecast: Market Share (%) by National Markets, 2026
Figure 4.1 US Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%) 2004-2015
Figure 4.2 US Generic Drugs Market Forecast: Revenue ($bn), AGR (%), 2014-2026
Figure 5.1 The EU5 Generic Drugs Market: Revenues ($bn) by Country, 2014
Figure 5.2 The EU5 Generic Drugs Market: Revenues ($bn) by Country, 2015
Figure 5.3 Germany, France, UK, Italy, and Spain Generic Drugs Market Forecast: Revenue ($bn), 2014-2026
Figure 5.4 The EU5 Generic Drugs Market: Market Share (%) by Country, 2014
Figure 5.5 The EU5 Generic Drugs Market: Market Share (%) by Country, 2020
Figure 5.6 The EU5 Generic Drugs Market: Market Share (%) by Country, 2026
Figure 5.7 The German Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2014-2026
Figure 5.8 German Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%), 2000-2015
Figure 5.9 German Generic Drugs Market: Generic Penetration by Value (%) and AGR (%), 2000-2015
Figure 5.10 The UK Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2014-2026
Figure 5.11 UK Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%), 2000-2015
Figure 5.12 UK Generic Drugs Market: Generic Penetration by Value (%) and AGR (%), 2000-2015
Figure 5.13 The French Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2014-2026
Figure 5.14 French Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%), 2000-2015
Figure 5.15 French Generic Drugs Market: Generic Penetration by Value (%), 2000-2015
Figure 5.16 The Italian Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2014-2026
Figure 5.17 Italian Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%), 2000-2015
Figure 5.18 Italian Generic Drugs Market: Generic Penetration by Value (%) and AGR (%), 2000-2015
Figure 5.19 The Spanish Generic Drugs Market Forecast: Revenue ($bn), AGR (%) , 2014-2026
Figure 5.20 Spanish Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%), 2000-2015
Figure 5.21 Spanish Generic Drugs Market: Generic Penetration by Value (%) and AGR (%), 2000-2015
Figure 6.1 China, Japan and India Generic Drugs Market Forecast: Revenue ($bn), 2014-2026
Figure 6.2 The Chinese Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2014-2026
Figure 6.3 Chinese Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%), 2000-2015
Figure 6.4 Chinese Generic Drugs Market: Generic Penetration by Value (%) and AGR (%), 2000-2015
Figure 6.5 The Japanese Generic Drugs Market Forecast: Revenue ($bn), AGR (%), 2014-2026
Figure 6.6 Japanese Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%) 2000-2015
Figure 6.7 Japanese Generic Drugs Market: Generic Penetration by Value (%) and AGR (%) 2000-2015
Figure 6.8 The Indian Generic Drugs Market Forecast: Revenue ($bn), AGR (%), 2014-2026
Figure 6.9 Leading Drug Types in Indian Pharmaceutical Market: Market Share (%), 2015
Figure 6.10 Leading Drug Types in Indian Pharmaceutical Market: Market Share (%), 2020
Figure 6.11 Leading Drug Types in Indian Pharmaceutical Market: Market Share (%), 2026
Figure 7.1 Brazil, Russia, Mexico, South Korea and Turkey Generic Drugs Market Forecast: Revenue ($bn), 2014-2026
Figure 7.2 The Brazilian Generic Drugs Market Forecast: Revenue ($bn), AGR (%), 2014-2026
Figure 7.3 The Russian Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2014-2026
Figure 7.4 The Mexican Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2014-2026
Figure 7.5 The South Korean Generic Drugs Market Forecast: Revenue ($bn), AGR (%), 2014-2026
Figure 7.6 The Turkish Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2014-2026
Figure 8.1 Top Generic Drugs Manufacturers: Generic Drugs Revenue ($bn), 2014
Figure 8.2 Top Generic Drugs Manufacturers: Generic Drugs Revenue ($bn), 2015
Figure 8.3 Teva: Historical Generic Drugs Sales ($bn) and AGR (%), 2010-2014
Figure 8.4 Teva Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2014-2026
Figure 8.5 Allergan: Historical Generic Drugs Sales ($bn) and AGR (%), 2010-2014
Figure 8.6 Novartis: Historical Generic Drugs Sales ($bn) and AGR (%), 2010-2014
Figure 8.7 Novartis Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2014-2026
Figure 8.8 Mylan: Historical Generic Drugs Sales ($bn) and AGR (%), 2010-2014
Figure 8.9 Mylan: Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2014-2026
Figure 8.10 Pfizer: Historical ‘Established Products’ Drugs Sales ($bn) and AGR (%), 2010-2014
Figure 8.11 Pfizer Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2014-2026
Figure 8.12 Hospira: Historical Specialty Injectables Sales ($bn) and AGR (%), 2010-2014
Figure 8.13 Abbott: Historical Generic Drugs Sales ($bn) and AGR (%), 2010-2014
Figure 8.14 Abbott Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2014-2026
Figure 8.15 Sun Pharma: Historical Generic Drugs Sales (Rs.bn) and AGR (%), 2010-2014
Figure 8.16 Sun Pharma: Historical Generic Drugs Sales ($bn) and AGR (%), 2010-2014
Figure 8.17 Sun Pharma Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2014-2026
Figure 8.18 Aspen: Historical Revenue ($bn) and AGR (%), 2010-2014
Figure 8.19 Aspen: Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2014-2026
Figure 8.20 Fresenius Kabi: Historical Generic Drugs Sales (€bn) and AGR (%), 2010-2014
Figure 8.21 Fresenius Kabi: Historical Generic Drugs Sales ($bn) and AGR (%), 2010-2014
Figure 8.22 Fresenius Kabi Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2014-2026
Figure 8.23 Sanofi: Historical Generic Drugs Sales ($bn) and AGR (%), 2010-2014
Figure 8.24 Sanofi Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2014-2026
Figure 9.1 World 65+ Population Forecast: Size (m) and AGR (%), 2014-2026
Figure 9.2 Porter’s Five Force Analysis of the Global Generic Drugs Market, 2016
Figure 10.1 Global Generic Drugs Market Forecast: Revenue ($bn), 2014, 2020 and 2026
Figure 10.2 US, Japan and EU5 Generic Drugs Market Forecast: Revenue ($bn), 2014-2026
Figure 10.3 BRIC Generic Drugs Market Forecast: ($bn), 2014-2026
Figure 10.4 Mexico, South Korea, and Turkey Generic Drugs Market Forecast: Revenue ($bn), 2014-2026
Figure 10.5 Generic Drug Penetration by Volume in Leading National Markets (%), 2015

★調査レポート[ジェネリック医薬品の世界市場予測2016-2026]販売に関する免責事項
★調査レポート[ジェネリック医薬品の世界市場予測2016-2026]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆